Latest Breaking News On - Analyst silvan tuerkcan - Page 1 : comparemela.com

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target .

Silvan tuerkcanEuropean unionAnalyst silvan tuerkcanCrispr therapeuticsResearch reportSickle cell diseaseTransfusion dependent thalassemiaTruist financialTipranks premium